encounter for operation and hospitalization accounted for the majority (74%) of the overall CM. The largest component (50.3%) of DC for FEVAR at the index encounter was implant/graft expenses (Fig 1) . The average DCs of FEVAR and of open repair for the index encounter were $34,600 and $35,000, respectively. The average CM for FEVAR vs open repair was approximately $10,500 vs $21,200, attributable to differences in reimbursement. The average DC of FEVAR trended down over time as cumulative experience increased. Average reimbursement per FEVAR increased after Centers for Medicare and Medicaid Services-approved reimbursement with the investigational device exemption (IDE) trial for PMEG in 2011 and a new technology add-on payment in 2012. These trends resulted in a transition from negative to positive average CM in 2012 (Fig 2) . The average physician payments for PMEG increased from $128 before to $5848 after the start of the IDE trial. Objective: Studies of major amputation after initial minor amputation are limited; rates of subsequent major amputation range from 14% to 34%, with a limited understanding for associated comorbidities and time to subsequent amputation. We sought to determine major amputation rates for patients who undergo initial minor amputation and to determine which factors are associated with limb preservation with open vs endovascular treatment.
Initial Open Versus Endovascular Treatment and Subsequent Limb Loss After Primary Minor Amputation
Jonathan H. Lin, Sun Young Jeon, Patrick S. Romano, Matthew W. Mell, Misty D. Humphries. University of California, Davis, Sacramento, Calif
Objective: Studies of major amputation after initial minor amputation are limited; rates of subsequent major amputation range from 14% to 34%, with a limited understanding for associated comorbidities and time to subsequent amputation. We sought to determine major amputation rates for patients who undergo initial minor amputation and to determine which factors are associated with limb preservation with open vs endovascular treatment.
Methods: Using statewide data, we identified patients with peripheral artery disease (PAD), diabetes mellitus (DM), and both PAD and DM (PD) with a lower extremity ulcer who underwent minor amputation from 2005 to 2013. We studied rates of subsequent major amputation and time to amputation and used Cox proportional hazards modeling to study which factors affect risk of subsequent major amputation.
Results: From 2005 to 2013, there were 11,597 patients (DM, 4254; PAD, 2142; PD, 5201) with ulcers who underwent minor amputation. The rate of subsequent amputation was highest in patients with PD (23% vs 17% for DM patients and 17% for PAD patients; P ¼ NS). The rate of subsequent minor amputation was 16% in the PD group vs 15.2% in PAD patients and 12.2% in DM patients. Patients with PD had the highest rate of subsequent major amputation (6.3% vs 5.2% for DM patients and 2.1% for PAD patients; P ¼ NS). The median time to major amputation was lowest in patients with PAD (8.5 months vs 14 months for DM patients and 13 months for PD patients; P ¼ NS). There was no difference in risk of subsequent major amputation for patients who underwent initial open revascularization vs endovascular therapy (hazard ratio, 0.92; confidence interval, 0.92-1.04). There was also no difference in time to subsequent major amputation between open and endovascular therapy (9.8 vs 8.7 months; P ¼ NS). In multivariable analysis, patients who could be treated completely in the outpatient setting were less likely to undergo amputation (hazard ratio, 0.7; confidence interval, 0.5-0.99) compared with those who required hospitalization or presented to the emergency department.
Conclusions: Patients with ischemic ulcers and diabetes are at the highest risk for subsequent major and minor amputation, with most occurring within a year of the initial minor amputation. Initial endovascular treatment did not increase the risk of subsequent major amputation compared with open, and there was no difference in time to amputation, indicating that the endovascular first approach may be reasonable for patients with critical limb ischemia. Author Disclosures: J. H. Lin: Nothing to disclose; S. Young Jeon: Nothing to disclose; P. S. Romano: Nothing to disclose; M. W. Mell: Nothing to disclose; M. D. Humphries: Nothing to disclose.
Factors Associated With Microembolization After Carotid Intervention
Joseph Sabat, Tze-Woei Tan, Craig Weinkauf, Theodore Trouard, Gloria Guzman, Wei Zhou. University of Arizona, Tucson, Ariz
Objective: Microembolization after carotid artery stenting (CAS) and carotid endarterectomy (CEA) has been documented and may confer risk for neurocognitive impairment. Patients undergoing stenting are known to be at higher risk for microemoblization. In this prospective cohort study, we compare the microembolization rates for patients undergoing CAS and CEA and patient and perioperative characteristics that may be associated with microembolization.
Methods: Patients undergoing CAS and CEA were prospectively recruited under local Institutional Review Board approval from an academic medical center. All patients also received 3T brain magnetic resonance imaging with a diffusion-weighted imaging sequence preoperatively and within 48 hours postoperatively to identify procedure-related new embolic lesions. Preoperative, postoperative, and procedural factors and plaque characteristics were collected. Factors were tested for statistical significance with logistic regression.
Results: There were 202 patients enrolled in the study; 107 underwent CAS and 95 underwent CEA. Patients undergoing CAS were more likely to have microemboli than patients undergoing CEA (78% vs 27%; 
